TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05548946

Intervention type: OTHER
Group type: OTHER
Intervention: Secondary Questionnaires (self-report and informant questionnaires)
Description: The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young \& Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse \& Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, \& Ettema, 1975, 1986, 2005) ADP-IV (Schotte \& De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver \& White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young \& Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical Ratings of the dimensional model
Description: Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~* The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~* The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)
Description: In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
Study: NCT06690905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam administered in a prolonged infusion
Description: For patients with the prolonged infusion intervention, the piperacillin-tazobactam dose will be administered via 100 ml 0.9% NaCl mini-bags infused and a volumetric pump over 3 hours for piperacillin-tazobactam dosages every 6 hours or overs 4 hours for piperacillin-tazobactam dosages every 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam administered in a standard infusion
Description: For patients with the standard infusion intervention, the piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)
Study: NCT06703567

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Policy
Description: Patients will receive information about the GEP test by clinical teams

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Policy + GEP Information Film
Description: Patients will receive information about the GEP test by clinical teams and, after consultation with physician, they will be sent a link to view the film regarding OncotypeDX
Study: NCT06725472

Intervention type: PROCEDURE
Intervention: Open Heart Surgery
Description: This is a general term for surgical procedures that directly access the heart through an opening in the chest to treat heart problems.

Intervention type: PROCEDURE
Intervention: Open Heart Surgery
Description: This is a general term for surgical procedures that directly access the heart through an opening in the chest to treat heart problems.
Study: NCT06727253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycan
Description: The post-operative CD patients will receive an orally administered glycan.
Study: NCT06725953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory-based, Technology-delivered Physical Activity Program
Description: Participants will engage in a 12-week program of aerobic and muscle-strengthening physical activity. This program will be delivered remotely via two smartphone applications--one for providing health education, goal setting, and journaling features and the other for delivery of the physical activity program in a highly-personalized and HIPAA-compliant manner. Participants will receive a Fitbit to track their activity and resistance bands to use during their resistance training physical activity. All program components will be based in the Social Cognitive Theory and will target improving participants' physiological and psychological health outcomes.
Study: NCT06725654

Intervention type: OTHER
Intervention: Diagnostic Procedures
Description: To evaluation the oral and dental health of orphaned children, DMFT, deft, GI, PI and CPITN indices were used to assess dental caries experience, gingival inflammation, the amount of plaque on the tooth surface and periodontal status, respectively.
Study: NCT05428475

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET Scan
Description: 185 MBq of \[18F\]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
Study: NCT06344676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relational
Description: Unrestricted individual interaction of the user with the Pepper robot to obtain information of interest for the user (menu, time, date, place and calendar of activities of the residential. center) and 1 individual monthly videoconference with the family of 10 minutes of duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Attentions and treatments received by the persons before the enrollment in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Attentions and treatments received by the persons before the enrollment in the study.
Study: NCT05880069

Intervention type: OTHER
Intervention: Pathogen resistant phenotype
Description: Drug resistant phenotype of the target pathogen under study

Intervention type: OTHER
Intervention: Pathogen resistant phenotype
Description: Drug resistant phenotype of the target pathogen under study
Study: NCT05976880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment of isometric hand grip training exercises
Description: In control group, conventional treatment perform by using isometric hand grip training exercises (putty grip and squeeze exercise, thumb pinch z strengthening exercises, isometric Hooks exercises, rubber band abduction and c thumb exercises) for 3times a week in one month.
Study: NCT06032026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-HY-2-15 PET
Description: 2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-HY-2-15

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: brain MRI
Description: brain MRI scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: PET scan with Florbetaben F18 or 11C-PiB

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurological assessments
Description: Neurological assessments, including video interview
Study: NCT05953610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 MG QHS
Description: Acetazolamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 MG QHS
Description: Acetazolamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg QHS
Description: Eszopiclone
Study: NCT04766658

Intervention type: OTHER
Group type: OTHER
Intervention: Gargle Phonation
Description: Subjects will gargle water while making sound

Intervention type: OTHER
Group type: OTHER
Intervention: Water swallow
Description: Subjects will hold water in their mouth for 5 seconds and swallow
Study: NCT04494334

Intervention type: PROCEDURE
Intervention: Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis
Description: Blood samples and Nasosorption sampling

Intervention type: PROCEDURE
Intervention: Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis
Description: Blood samples and Nasosorption sampling
Study: NCT05765318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
Study: NCT05041218

Intervention type: OTHER
Intervention: Neural Interfaces Electroencephalogram measurement on Operators
Description: Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
Study: NCT05458791

Intervention type: DEVICE
Intervention: Intra-arterial Perfusion
Description: All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.

Intervention type: DEVICE
Intervention: Intra-arterial Perfusion
Description: All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
Study: NCT04940091

Intervention type: DRUG
Intervention: Epidural analgesia
Description: Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
Study: NCT05375110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoYA™ Radiofrequency Interatrial Shunt System
Description: NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
Study: NCT04800510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
Study: NCT04748549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Immersive Relaxation
Description: The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Audio Experience
Description: A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Virtual Reality Experience
Description: Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
Study: NCT05853081

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance analysis
Description: The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance analysis
Description: The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance analysis
Description: The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
Study: NCT05543226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHGG-rich enteral nutrtiion
Description: PHGG-rich enteral nutrition
Study: NCT05217758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 1200 mg/day, once daily, 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, 7 days
Study: NCT05976880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment along with power ball training
Description: In experimental group, 3sessions per week and total 12 training sessions in a month will be perform. In this session, conventional treatment perform with power ball exercise should be done for 3 minutes in a day, where power ball can initially alleviate the pain, then make them feel strong and in the end persons feel strengthen with pain free movements. Before start training with a power ball, hand held dynamometer will use prior to the first session, on 7th session of training and after 12th training session. So that changes in hand grip strength can be measured by dynamometer.
Study: NCT05710614

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Animal protein
Description: Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) animal-based protein (i.e.; whey protein) in drink form as a supplementary source of protein in their main meals of the day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant Protein
Description: Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) mixed plant protein (i.e.; soy and pea) in drink form as a supplementary source of protein in their main meals of the day.
Study: NCT05543226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PHGG-rich enteral nutrtiion
Description: PHGG-rich enteral nutrition
Study: NCT06353217

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Group (Hypoglycemia Prevention Program)
Description: The Hypoglycemia Prevention Program:~The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Primary Care Physician Group
Description: The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinic Staff Group
Description: Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.
Study: NCT04836832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO
Study: NCT06167759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Use Agreement
Description: This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
Study: NCT06727214

Intervention type: DRUG
Intervention: Chemotherapy with platine
Description: medical records that patients received neoadjuvant systemic chemotherapy platine based
Study: NCT05880758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Short Sleep (ISS)
Description: Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Short Sleep (ISS)
Description: Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Jetlag (SJL)
Description: 2-hour delayed sleep timing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Adequate Sleep (SAS)
Description: Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
Study: NCT06103617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillamine
Description: Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
Study: NCT05866159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape using Rocktape®
Description: Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
Study: NCT06523686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration
Description: Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration
Description: Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.
Study: NCT05264662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adacel (Tdap)
Description: Administer Adacel to hiv infected and hiv uninfected pregnant mothers
Study: NCT05866159

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: sham taping with Rocktape®, with no tension.
Study: NCT05492240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: i-STRONGER
Description: An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Clinicians will tailor the intervention for each activity, so the patient achieves 8 repetitions with failure on the 9th repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Furthermore, a combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.